Table 5 Association between histological active inflammation and clinical characteristics
Characteristic | Active inflammation N = 129 | No-active inflammation N = 53 | P value |
|---|---|---|---|
Time from ICPI to onset (months, SD) | 3 (4) | 5 (9) | 0.014 |
Duration of symptoms (days, SD) | 39 (96) | 17 (21) | 0.102 |
Diarrhea grade, n (%) | 0.001 | ||
1 | 9 (7.0) | 15 (28.3) | |
2 | 43 (33.3) | 17 (32.1) | |
3–4 | 77 (59.7) | 21 (39.6) | |
Colitis grade, n (%) | 0.012 | ||
1 | 19 (14.7) | 18 (34.0) | |
2 | 63 (48.8) | 23 (43.4) | |
3–4 | 47 (36.4) | 12 (22.6) | |
IV steroids, n (%) | 71 (54.0) | 13 (24.5) | < 0.001 |
Duration of steroid (days, SD) | 67 (77) | 37 (34) | 0.083 |
Infliximab/vedolizumab, n (%) | 39 (33.6) | 3 (12.0) | 0.032 |
Colonoscopy findings, n (%) | < 0.001 | ||
Ulcer | 49 (38.0) | 0 (0.0) | |
Non-ulcerative inflammation | 51 (39.5) | 15 (28.3) | |
Normal | 29 (22.5) | 38 (71.7) | |
High-risk endoscopic features, n (%) | 63 (48.8) | 8 (15.1) | < 0.001 |
Outcomes, n (%) | |||
Hospitalization | 98 (76.0) | 34 (64.2) | 0.143 |
Duration of hospitalization (days, SD) | 8 (6) | 6 (8) | 0.196 |
ICU admission | 2 (1.6) | 5 (9.4) | 0.023 |
Recurrence | 44 (34.1) | 7 (13.2) | 0.004 |
Repeat endoscopy | 32 (24.8) | 4 (7.5) | 0.007 |